Tear proteomics analysis of patient suffered from delayed mustard gas keratopathy

Shahram Parvin1,2, Alireza Shahriary1, Hossein Aghamollaei1, B. Fatemeh Nobakht M. Gh1, Hasan Bagheri1, Mostafa Ghanei1, Seyed-Hashem Daryabari1, Khosrow Jadidi1 and Masoud Arabfard1*

Abstract
Understanding the molecular and cellular mechanisms involved in the pathogenesis of ocular injured induced by mustard gas can help better identify complications and discover appropriate therapies. This study aimed to analyze the proteomics of tears of chemical warfare victims with mustard gas ocular injuries and compare it with healthy individuals. In this case-control research, 10 mustard gas victims with long-term ocular difficulties (Chronic) were included in the patient group, while 10 healthy persons who were age and sex matched to the patients were included in the control group. Schirmer strips were used to collect the tears of the participants. Proteomics experiments were performed using the high-efficiency TMT10X method to evaluate the tear protein profile, and statistical bioinformatics methods were used to identify the differently expressed proteins. 24 proteins had different expressions between the two groups. Among these 24 proteins, 8 proteins had increased expression in veterans’ tears, while the remaining 16 proteins had decreased expression. Reactome pathways were used to look at proteins with various expressions, and 13 proteins were found to be engaged in the immune system, 9 of which were effective in the innate immune system, and 5 proteins were effective in the complement cascade. Ocular mustard gas exposure may cause a compromised immune system on the eye’s surface, exposing the cornea to external and endogenous infections, and eventually causing corneal opacity and reduced vision.

Keywords: Proteomics, Sulfur mustard, Ocular complications, Tear
eye, which may be impacted at quantities 10 times lower than those needed to induce respiratory or cutaneous damage [6]. Even 30 years after their first exposure to sulfur mustard, 65% of veterans suffered from ocular issues, according to a research done by Balali-Mood and his colleagues [4]. The ocular complications of mustard gas are divided into two categories: acute and delayed complications. Eye pain, foreign body feeling, burning, anterior uveitis, conjunctivitis, photophobia, and temporary blindness are some of the acute consequences. Chronic inflammatory processes, sulfur mustard metabolites, and autoimmune responses might cause delayed consequences after an asymptomatic period. The most important delayed complications include neovascularization, corneal haze and scarring, corneal dystrophy, limbal stem cells defect, corneal thinning, limbus ischemia and lipid and amyloid deposition in the cornea [7–11].

Currently no definitive treatment exists for ocular complications of sulfur mustard. At the first stage of injuries, some medications including washing the eyes with plenty of water or normal saline, using sodium bicarbonate, dichloramine, artificial tears, topical antibiotics, corticosteroids, and miidriatic agents can be used [8, 12]. Artificial tears, anti-inflammatory therapies, immunomodulatory pharmaceuticals, human blood derivatives, amniotic membrane transplantation, tarsoraphy, stem cell transplantation, and corneal transplantation are some of the pharmacological and surgical treatments for delayed problems [8, 13]. Understanding the molecular and cellular mechanisms involved in the pathogenesis of mustard gas keratopathy aids in identifying complications and discovering appropriate therapies. One of the ways to better understand the pathogenesis of diseases is to study the proteome of the organs involved. Proteomics is a studies that can detect protein changes in different tissues. Protein studies have been previously performed using antibodies and methods, such as Western blotting and ELISA that allowed for the examination of a limited number of proteins that were abundantly present in the sample. However, due to technological advancements and the advent of mass spectrometry, it is now feasible to analyze a wide range of proteins, even those with low abundance in varied samples. The most recent mass spectrometry technology is the iTRAQ, which is the most accurate in detecting proteins even with a small amount [14], and was used in this study to better evaluate the tear proteome. Moreover, in this study, we used the latest Tandem Mass tag (TMT) method, known as TMT10X, to better and more accurately identify proteins compared to earlier methods using gel or antibody assays [15]. Numerous proteomics research on various illnesses have been conducted in the recent decade, leading to a better knowledge of disease pathophysiology and the development of novel treatment methods [16]. Proteomics may also aid in the accurate diagnosis of illnesses, the prediction of disease outcomes, and the monitoring of patients. This study aimed to analyze the proteome of tear in warfare veterans with sulfur mustard ocular complications and compare it with healthy individuals, using the proteomics approach. Understanding the changes in the tear proteome of these patients may help better understand the pathogenesis of mustard gas ocular complications and be a prelude to devising more effective therapeutic approaches for these patients.

**Materials and methods**

**Patients and controls**

The study was approved by the Institutional Review Board and the Ethical Committee of Baqiyatallah University of Medical Sciences (code: IR.BMSU.REC.1395.381). The consent form was signed by all of the individuals that were recruited. Ten patients and ten controls who were matched in sex and age were enrolled in the research after completing the questionnaire and providing informed permission. Patients required to have medical records and their delayed mustard injuries had to be validated by specialist ophthalmologists to be included in the study. Besides, all moderate to severe confirmed DMGK patient with ischemia in the conjunctiva and limbus, vascular penetration to the corneal periphery, with or without opacity, corneal thinning and melting. All the subjects were adult and non-smokers and aged between 45 and 60 years. Furthermore, history of previous eye surgery, systemic disease including diabetes, blood pressure, chronic kidney disease, current eye infection, or diseases such as glaucoma, taken corticosteroids or other specific drugs for 2 weeks, seasonal allergies in the last 6 months, and treated with antibiotics for 2 weeks were excluded. Tear sampling was done by Schirmer strip (ERC, Turkey). Tears were collected without the use of any anesthetics. For 5 minutes, Schirmer paper was put at the outside third of the lower eyelid’s margin (below the fornix). The paper was then removed and put in the nuclease-free tube before being transported to the −80 freezer.

**Sample preparation**

For protein extraction, Schirmer strips were cut to the 2'2 mm and transferred to the 1.5 ml sterile micro tube. 800ul of 1% sodium deoxycholate in 100 mM NH4HCO3 was added to the samples and vortexed vigorously, the samples were centrifuged at 5000 RPM. The protein solution was lyophilized and wrapped in the cap using parafilm.

Protein concentrations were determined using BCA assay (Thermo Scientific, USA) as per manufacturer’s instruction. Cysteine disulphide bonds in the proteins
were reduced with 10 mM DTT at 37 °C for 1 h, and then alkylated with 20 mM IAA for 45 min in dark at room temperature. Remaining IAA in the samples were quenched with 10 mM DTT for 15 min in the dark at room temperature. Samples were proteolyzed with Lys-C (100:1 protein to enzyme ratio) overnight at 28 °C, then digested with trypsin (100:1 protein to enzyme ratio) for 6 hours at 37 °C. The sample was desalted using a solid phase extraction disk containing Stage tips and Styrene Divinyl Benzene after the pH was adjusted to roughly 3 with a final concentration of around 1% TFA (Empore SDB-RPS 47 mm extraction disk, SUPLCO). Peptides were bonded to stage tips, washed with 0.2% TFA, and then eluted with 80% acetonitrile: 5% ammonium hydroxide. The peptides were vacuum centrifuged before being reconstituted in 200 mM HEPES pH 8.8 and measured using the Pierce quantitative colorimetric peptide assay (Thermo Scientific, USA).

### Sample labelling

TMT reagent labelling of peptides was performed as per manufacturer's (Thermo Scientific, USA) instructions. Each TMT label vial was filled with anhydrous acetonitrile, vortexing for 5 minutes, and centrifugation. One of the individual TMT labels was applied to aliquots of individual peptide samples (total of ten labels). Labeling took place at room temperature for 1 hour, with some vortexing in between. TMT labelling scheme for each sample is listed in Table 1.

To quench the excess TMT label in the sample, 5% hydroxylamine was added to each of the sample and vortexed then incubated at RT for 15 min. Before pooling the samples, to ensure equal amount of total peptides are pooled from all samples, a “label check” experiment was performed by mixing 1.5 μL of each individually labelled TMT sample, vacuum dried. Samples were reconstituted in 2% ACN, 0.1% FA in water and analysed by LC-coupled to a mass spectrometer (Q-Exactive, Thermo Fisher, USA). TMT-labeled peptide samples were pooled at a 1:1 ratio across all samples and vacuum dried after the label check experiment gave a normalisation factor. The samples were vacuum centrifuged to dryness after desalting with C18 solid-phase extraction (SPE, Sep-Pak, Waters). Prior to LC-MS/MS analysis, the peptide mixture was separated into 96 fractions using high pH (Hph) reverse phase HPLC, and then consolidated into 17 fractions. The Hph HPLC fractions from each TMT set were reconstituted using sample loading buffer (2% acetonitrile, 97.9% water, 0.1% formic acid) before LC-MS/MS analysis.

#### LC–MS/MS analysis

1D data dependent acquisition (DDA) of peptides on Q-exactive quadrupole-Orbitrap (QE-classic)

Peptide samples which were TMT labelled were inserted onto an in-house packed trap column and desalted using loading buffer. Peptides were eluted from the trap into an in-house packed analytical column using linear mobile phase A and B gradients: mobile phase B (30%) over 110 minutes at a flow rate of 300 nL/min throughout the gradient.

The eluent was separated from the trap using an analytical column. The eluent from the column was injected into the ionisation source of the mass spectrometer. A 2.6 kV electrospray voltage was applied through a liquid connection upstream of the column. Peptide precursors from 350 to 1850 m/z were scanned at 70k resolution with an AGC target value of 1 × 106. Higher-Energy Collisional Dissociation (HCD) was used to fragment the 10 most energetic ions from the previous survey scan, with a normalised collision energy of 35 and an isolation width of 0.7 m/z. MS/MS analysis is limited to precursors with a charge state of +2 to +4. For MS2 triggering, the MS technique had a minimum signal needed value of 2.5 × 104, an AGC target value of 2105, and a maximum injection duration of 250 ms. The resolution of the MS/MS scan was set at 70k. The duration of the dynamic exclusion was set to 90 seconds.

#### Protein identification and quantification

The mass spectrometric data files for each sample set were searched using Proteome Discoverer (version 2.1, Thermo Scientific). uniprot database (181005_UniPr_HUMAN_Revi+Unrevi.fasta, Ref: http://www.uniprot.org) containing 95,106 human proteins including isoforms and unreviewed (Homo sapiens) was used for searching the data. The quantitative ratios were generated

---

**Table 1** The TMT labelling scheme used for each individual tear sample

| TMT Labels (tear samples) | TMT-1       | TMT-2       |
|---------------------------|-------------|-------------|
| 126                       | T2(Control) | T2(Control) |
| 127N                      | T1(Control) | T13(Control) |
| 127C                      | T7(Control) | T15(Control) |
| 128N                      | T8(Control) | T17(Control) |
| 128C                      | T9(Control) | T19(Control) |
| 129N                      | T3(Patient) | T11(Patient) |
| 129C                      | T4(Patient) | T12(Patient) |
| 130N                      | T5(Patient) | T14(Patient) |
| 130C                      | T6(Patient) | T16(Patient) |
| 131                       | T10(Patient)| T18(Patient)|
using the quantitative values found in channel 126 (control) as denominator.

**Statistical analysis**

The differentially abundant proteins were analyzed using the Limma Packages, which are written in R. The Bioconductor software was used to analyze the data, which fits a linear model to each protein and then uses the Bayes technique to the predicted variances to increase power. Comparison of normalized protein areas between control and patient samples (Fig. 2) showed a total of 24 differentially abundant proteins (Fold change 1 ± 0.2,
statistically significant differences between patient and control were accepted as \( p\)-value< 0.05) in tear samples (Fig. 3). The reason for choosing this Fold change was due to the chronic nature of the disease. By selecting a higher threshold, it is difficult to find the altered proteins for patients with chronic disease. Moreover, regarding the limited number of samples, Adaptation of Adjusted \( p\)-value for a low number of samples limits the validation of significant proteins.

**Results**

TMT quantitative proteomic analysis of human samples resulted in the identification 3586 high confident (Protein, Peptide and PSM FDR<1%) proteins in tear samples. A relative abundance comparison was performed using a density plot and Box Plot analysis of normalized data (Fig. 1). Because all samples within each data set have similar protein ratio distributions (ratio with reference to channel 126, a control sample), a relative abundance comparison was performed.

One way to pre-process and detect outlier data is to use a heatmap plot that helps visualize hierarchical clustering. Using heatmap package in R, the detection of the outlier sample was performed, which can be seen in Fig. 2. By analyzing the heatmap, it was found that there is no outlier and all samples were analyzed for the next step.

After the data preprocessing and grouping the samples, the list of all differentially abundant proteins was calculated using the Lima package in R language. The final output of this analysis is shown in Fig. 3 as a volcano plot.

The tear protein profiles of 10 healthy individuals and 10 veterans with mustard gas ocular poisoning were compared and our results showed that 24 proteins had different expressions between two groups. As shown in Table 2, of these 24 proteins, 8 proteins had increased expression in veterans’ tears, while the remaining 16 proteins had decreased expression.

Reactome pathways were used to investigate proteins with various expressions in order to determine the activities and pathways involved (Table 3). Thirteen of the 24 proteins were found to be involved in the immune system, with nine of them being engaged in the innate
immune system. In addition, five proteins participated in the complement cascade.

Proteins with different expressions were examined using Gene Ontology (GO) to determine in what part of the cell they are located (Table 4). Of these 24 proteins, 11 proteins were extracellular components.

### Discussion

The tear protein profiles of 10 veterans with long-term ocular complications due to mustard gas poisoning were compared with the tears of healthy individuals. Our results showed the dysregulated expression of 24 proteins in patients compared to controls, and this could be the key to understanding the pathogenesis of ocular mustard gas poisoning and help find more appropriate treatments for these patients. Thirteen of the 24 proteins with different expressions were involved in immune-related processes, and six proteins were involved in complement cascade function. As a result, it seems that a disturbance in these two biological systems is the primary cause of eye difficulties in mustard gas poisoning patients. TFF3 protein was found to be elevated in our patients’ tears. The expression of this protein is not detectable in normal circumstances and healthy corneas, but it is detectable and enhanced in pathological situations such as Fox dystrophy, herpes keratitis, keratoconus, and pterygium [17, 18]. It was shown that the expression of this protein increases after corneal epithelial damage in mice [19]. This protein binds to mucins and is involved in the packaging and secretion of mucins, thereby altering the flow and concentration of mucus [20]. In the patients with dry eye disease, the expression of this protein increases in terms of corneal damage and similar stressors that cause inflammation [21]. TFF3 is known as the initiator of the wound healing process, which does this by increasing the migration of adjacent epithelial cells. This protein, on the other hand, causes apoptosis and destroys the extracellular matrix in chronic inflammatory situations by activating certain MMPs [17]. Given that increased TFF3 expression activates MMPs, destroys the extracellular matrix, induces apoptosis, and continues the inflammatory process at the corneal surface, it can be concluded that increased TFF3 expression activates MMPs, destroys the extracellular matrix, induces apoptosis, and continues the inflammatory process at the corneal surface. Thus, this vicious cycle of inflammation - increased TFF3

### Table 2

| Accession ID | Protein Name                          | Gene name          | Fold change | P-value |
|--------------|---------------------------------------|--------------------|-------------|---------|
| Q07654       | Trefoil factor 3                       | TFF3               | 1.752       | 0.001   |
| Q8TAX7       | Mucin-7                               | MUC7               | 1.568       | 0.001   |
| Q8BJ23       | RNA cytosine C(5)-methyltransferase   | NSUN2              | 1.564       | 0.006   |
| Q52298       | Nuclear cap-binding protein subunit 2 | NCBP2              | 1.528       | 0.011   |
| P05161       | Ubiquitin-like protein ISG15           | ISG15              | 1.516       | 0.004   |
| Q7LG8        | Carbohydrate sulfotransferase 3       | CHST3              | 1.479       | 0.001   |
| A0A0G2JS65   | Mucin-4                               | MUC4               | 1.438       | 0.006   |
| P12273       | Prolactin-inducible protein            | PIP                | 1.437       | 0.044   |
| J3KN3        | Phosphorylase kinase                   | PHKG2              | 0.707       | 0.001   |
| P36957       | Dihydropolysine-residue succinyltransferase component of 2-oxoglutarate dehydrogenase complex, mitochondrial | DLST | 0.692 | 0.022 |
| P06276       | Cholinesterase                        | BCHE               | 0.689       | 0.001   |
| Q02318       | Sterol 26-hydroxylase, mitochondrial  | CYP27A1            | 0.684       | 0.021   |
| Q96BM9       | ADP-ribosylation factor-like protein 8A | ARLB8            | 0.681       | 0.031   |
| Q9NVJ2       | ADP-ribosylation factor-like protein 8B | ARLB8            | 0.681       | 0.031   |
| Q9BXB5       | Oxysterol-binding protein-related protein 10 | OSBP10           | 0.673       | 0.036   |
| P08123       | Collagen alpha-2(II) chain            | COL1A2             | 0.627       | 0.030   |
| P04003       | C4b-binding protein alpha chain       | C4BPA              | 0.621       | 0.038   |
| O75636       | Ficolin-3                             | FCN3               | 0.617       | 0.003   |
| P16403       | Histone H1.2                          | H1–2               | 0.616       | 0.006   |
| H3BSW6       | Cytoplasmic RNA 2-thiolation protein 2 | CTU2              | 0.610       | 0.001   |
| P20851       | C4b-binding protein beta chain        | C4BPB              | 0.574       | 0.002   |
| P01701       | Immunoglobulin lambda variable 1–51   | IGLV1–51           | 0.572       | 0.006   |
| Q9GZP8       | Immortalization up-regulated protein   | IMUP               | 0.458       | 0.002   |
| A0A075B6H4   | Immunoglobulin lambda variable 10–54  | IGLV10–54          | 0.425       | 0.008   |
expression - more inflammation can be one of the aspects of ocular mustard gas poisoning pathogenesis.

As mentioned above, TFF3 is involved in the secretion of mucins [20]. In our study, the amount of mucin 4 and 7 was higher in tears of patients than in the control

**Table 3** Processes and pathways that differentially expressed proteins are involved in based on Reactome pathways

| Pathway name                                                                 | Number of entities found | Number of total entities | Proteins involved (labels) |
|------------------------------------------------------------------------------|--------------------------|--------------------------|----------------------------|
| Complement cascade                                                          | 5                        | 156                      | FCN3, IGLV1–51; C4BPA, C4BPB, IGLV10–54 |
| Regulation of Complement cascade                                            | 4                        | 139                      | IGLV1–51; C4BPA, C4BPB, IGLV10–54 |
| Innate Immune System                                                        | 9                        | 1329                     | FCN3; IGLV1–51; MUC7; C4BPA; ISG15; C4BPB; MUC4; ARL8A; IGLV10–54 |
| Defective GALNT3 causes familial hyperphosphatemic tumoral calcinosis (HFTC) | 2                        | 20                       | MUC7; MUC4 |
| Defective GALNT12 causes colorectal cancer 1 (CRC51)                        | 2                        | 20                       | MUC7; MUC4 |
| Defective C1GALT1C1 causes Tn polyagglutination syndrome (TNPS)             | 2                        | 21                       | MUC7; MUC4 |
| Creation of C4 and C2 activators                                            | 3                        | 111                      | FCN3, IGLV1–51; IGLV10–54 |
| Termination of O-glycan biosynthesis                                        | 2                        | 28                       | MUC7; MUC4 |
| Initial triggering of complement                                            | 3                        | 120                      | FCN3; IGLV1–51; IGLV10–54 |
| Immune System                                                               | 13                       | 2869                     | FCN3; IGLV1–51; COL1A2; MUC7; C4BPA; ISG15; C4BPB; MUC4; ARL8A; IGLV10–54 |
| Binding and Uptake of Ligands by Scavenger Receptors                       | 3                        | 167                      | IGLV1–51; COL1A2; IGLV10–54 |
| Diseases of glycosylation                                                   | 3                        | 202                      | MUC7; MUC4; CHST3 |
| Dectin-2 family                                                             | 2                        | 65                       | MUC7; MUC4 |
| Diseases of metabolism                                                      | 4                        | 409                      | CYP27A1; MUC7; MUC4; CHST3 |
| tRNA modification in the nucleus and cytosol                                | 2                        | 70                       | CTU2; NSUN2 |
| O-linked glycosylation of mucins                                            | 2                        | 73                       | MUC7; MUC4 |
| Chondroitin sulfate/dermatan sulfate metabolism                             | 2                        | 73                       | PIP; CHST3 |
| Diseases associated with O-glycosylation of proteins                       | 2                        | 78                       | MUC7; MUC4 |
| Defective CYP27A1 causes Cerebrotendinous xanthomatosis (CTX)               | 1                        | 6                        | CYP27A1 |
| Cell surface interactions at the vascular wall                              | 3                        | 257                      | IGLV1–51; COL1A2; IGLV10–54 |
| Classical antibody-mediated complement activation                           | 2                        | 97                       | IGLV1–51; IGLV10–54 |
| Defective CHST3 causes SEDCCJD                                                | 1                        | 9                        | CHST3 |
| FCGR activation                                                             | 2                        | 103                      | IGLV1–51; IGLV10–54 |
| Scavenging of heme from plasma                                              | 2                        | 106                      | IGLV1–51; IGLV10–54 |
| Role of LAT2/NTAL/LAB on calcium mobilization                              | 2                        | 107                      | IGLV1–51; IGLV10–54 |
| SLBP independent Processing of Histone Pre-mRNAs                            | 1                        | 10                       | NCBP2 |
| SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs       | 1                        | 11                       | NCBP2 |
| GP1b–IX–V activation signalling                                             | 1                        | 12                       | COL1A2 |
| Ficolins bind to repetitive carbohydrate structures on the target cell surface | 1                        | 12                       | FCN3 |

**Table 4** Cellular components of differentially expressed proteins based on GO

| term description                          | observed gene count | background gene count | Proteins (labels) |
|--------------------------------------------|---------------------|-----------------------|-------------------|
| extracellular region                       | 11                  | 2505                  | BCHE, C4BPA, C4BPB, COL1A2, FCN3, IGLV1–51, IGLV10–54, ISG15, MUC4, PIP, TFF3 |
| extracellular region part                  | 8                   | 1375                  | C4BPA, C4BPB, COL1A2, IGLV1–51, IGLV10–54, MUC4, PIP, TFF3 |
| extracellular space                        | 7                   | 1134                  | C4BPA, C4BPB, COL1A2, IGLV1–51, IGLV10–54, PIP, TFF |
| other organism cell                        | 3                   | 36                    | C4BPA, C4BPB, MUC7 |
| spindle midzone                            | 2                   | 31                    | ARL8A, ARL8B |
group. However, similar to dry eye patients mucin glycolysis may be reduced in the patients with mustard gas poisoning [22], and increased mucin expression may be a secondary response to this reduction in glycolysis, which requires further research in this area. Mucins play a role in the humoral immune response and signaling process of type C lectin receptors, which are involved in complement activation [23], which may indicate a possible role for these proteins in the pathogenesis of ocular mustard gas poisoning.

PIP protein was significantly upregulated in the tear profile of our patients. The expression of this protein is reduced in patients with dry eye secondary to Sjogren’s disease [24]. Several additional studies showed that people with dry eye had lower levels of this protein in their tears [25–28]. This protein’s expression has also been demonstrated to be reduced in chronic blepharitis [15]. PIP, on the other hand, has been proposed as a Keratoconus biomarker since it is elevated in the tears of keratoconus patients [29]. The effect of PIP on creatine production in the stroma and corneal epithelial cells has also been reported and this indicates the role of this protein in the structural stability of the cornea [30]. Another point about this protein is its role in the immune system; this protein is a specific inhibitor of apoptosis induced by CD4+ T cells and thus has a regulatory role in innate and humoral immunity [31]. Increased expression of this protein was reported in patients with mycotic keratitis, thyroid eye disease and open-angle glaucoma [32–34].

In our study, the expression of PIP protein in the tears of veterans was higher than healthy individuals. According to previous studies and the role of this protein in regulating the immune system, its increased expression indicates impaired efficiency of immune system in responding to pathogens on the surface of patients’ eyes.

Among 24 proteins that had altered expression in this study, 5 proteins had roles in the function of the complement system, so examining the role of this system in eye diseases can be enlightening. The continuous circulation of the complement inside the eye and its role in the eye’s safety status is known [35, 36]. Complement plays an important role in maintaining corneal health [37]. CD46, CD55, and CD59 are membrane bound complement regulators that are expressed in diverse layers of the cornea, though they are more prevalent in the corneal epithelium [38]. This is significant because the cornea’s surface is continually exposed to numerous pathogens, including bacteria like P. aeruginosa, resulting in the complement system’s persistent activation [39]. In fact, some bacteria produce phospholipases and other enzymes that can remove CD55 and CD59 from the corneal epithelial surface, potentially predisposing the cornea to irregular activation of complement, which exacerbates bacterial keratitis (inflammation of the cornea) ultimately leading to vision loss [39, 40]. In general, just as the continuous function of the complement in the eye is good for maintaining corneal health, too much activity can cause uncontrolled inflammation and damage to the cornea. Therefore, balanced regulation of complement activity is required in the cornea to prevent damage.

According to the results of our study, the tears of patients with ocular mustard gas poisoning had lower levels of complement activating proteins (C4BPA, C4BPB, FCN3, IGLV10–54, IGLV1–51), so it seems that mustard gas pathogenesis can be linked to the reduced activity of complement system in these patients making the cornea more susceptible to pathogens, such as Pseudomonas and external toxic agents.

**Conclusion**

We found numerous dysregulated proteins in the tear profiles of patients with sulfur mustard poisoning, and analysis of their activities revealed that these proteins were most typically connected with the innate immune and complement pathways. As a result, it’s possible that abnormalities of the complement system and the innate immune system are involved in the pathogenesis of mustard gas ocular poisoning. In summary, mustard gas in the eye may lead to a weakened immune system on the surface of the eye, predisposing the cornea to pathogens, and ultimately causing corneal opacity and decreased vision. To confirmation and validation of this data, more experimentally research should be conducted on the complement system and innate immunity activity in the eye of these patients. After validation and confirmation of these finding in future studies, new drugs or protocols can be proposed for treatment of delayed mustard gas keratopathy.

**Abbreviations**

CWC: Chemical Weapons Convention; OPCW: Organization for the Prohibition of Chemical Weapons; TMT: Tandem Mass Tag; DDA: Data Dependent Acquisition; HCD: Higher-Energy Collisional Dissociation.

**Acknowledgements**

This research was supported by the Baqiyatallah University of Medical Sciences Sciences, Tehran, Iran. Aspects of this research have been facilitated by access to the Macquarie University trading as Australian Proteome Analysis Facility (APAF).

**Authors’ contributions**

A.S.H, H. B and M.GH conceived of the presented idea. Sh. P and H. A carried out the experiment. K. J and S.H.D carried out data gathering. M. A performed the computations. BFNM helped to revise the manuscript. All authors discussed the results and contributed to the final manuscript. The author(s) read and approved the final manuscript.
Funding
No funding was obtained for this study.

Availability of data and materials
The data that support the findings of this study are available from the corresponding author upon reasonable request.

Declarations
Ethics approval and consent to participate
This study involving human participants was in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the Institutional Review Board and the Ethical Committee of Baqiyatallah University of Medical Sciences (code: IR.BMSU.REC.1395.381). All recruited participants signed the consent form.

Consent for publication
Not applicable.

Competing interests
Authors have no conflict of interest to declare.

Author details
1Chemical Injuries Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran. 2Education Office, Pasteure Institute of Iran, Tehran, Iran.

Received: 18 December 2021 Accepted: 3 August 2022
Published online: 10 August 2022

References
1. Borak J, Sidell FR. Agents of chemical warfare: sulfur mustard. Ann Emerg Med. 1992;21(3):303–8.

2. Ghahbi K, Agutter PS, Ghaniel M, Ansarin K, Panahi Y, Shoa MM. Sulfur mustard toxicity: history, chemistry, pharmacokinetics, and pharmacodynamics. Crit Rev Toxicol. 2011;41(5):384–403.

3. Panahi Y, Abdolahaffari AH, Sahelbark A. A review on symptoms, treatments protocols, and proteomic profile in sulfur mustard-exposed victims. J Cell Biochem. 2018;119(1):197–206.

4. Balali-Mood M, Hefazi M. Comparison of early and late toxic effects of sulfur mustard in iranian veterans. Basic Clin Pharmacol Toxicol. 2006;99(4):273–82.

5. Kehe K, Szinicz L. Medical aspects of Sulphur mustard poisoning. Toxicology. 2011;214(3):198–209.

6. Hur G-H, Kim Y-B, Choi D-S, Kim J-H, Shin S. Apoptosis as a mechanism of 2-chloroethyl ethyl sulfide-induced cytotoxicity. Chem Biol Interact. 1998;110(1–2):57–70.

7. Panahi Y, Naderi M, Zare MA, Poursaleh Z. Ocular effects of sulfur mustard. Basic Clin Pharmacol Toxicol. 2006;99(4):273–82.

8. Panahi Y, Naderi M, Zare MA, Poursaleh Z. Ocular effects of sulfur mustard. Basic Clin Pharmacol Toxicol. 2006;99(4):273–82.

9. Javadi M-A, Yazdani S, Sajjadi H, Jadidi K, Karimian F, Einollahi B, et al. Chronic and delayed-onset mustard gas keratitis: report of 48 patients and review of literature. Ophthalmology. 2005;112(4):617–25.

10. Baradaran-Rafii A, Eslami M, Tseng SC. Sulfur mustard-induced ocular surface disorders. Ocul Surf. 2011;9(3):163–78.

11. Balali-Mood M, Hefazi M, Mahmoudi M, Jalali E, Attaran D, Maleki M, et al. Long-term complications of Sulphur mustard poisoning in severely intoxicated Iranian veterans. FundamClin Pharmacol. 2005;19(6):713–21.

12. Babin MC, Ricketts KM, Gazaway MY, Lee RB, Sweeney RE, Brozetti JJ. A combination drug treatment against ocular sulfur mustard injury. J Toxicol. 2005;23(1):65–75.

13. Javadi K, Panahi Y, Ebrahimi A, Mafi M, Nejar F, Sahelbark A. Topical cyclosporine a for treatment of dry eye due to chronic mustard gas injury. J OphthalmicVis Sci. 2014;9(4):171.

14. Shadforth IP, Dunkley TP, Lilleby KS, Bessant C. I-Tracker: for quantitative proteomics using iTRAQ™. BMC Genomics. 2005;6(1):145.

15. Moulder R, Bhosal SD, Goodlett DR, Lahesmaa R. Analysis of the plasma proteome using iTRAQ and TMT-based isobaric labeling. Mass Spectrom Rev. 2018;37(5):583–606.

16. Aghamolaii H, Parvin S, Shahriary A. Review of proteomics approach to eye diseases affecting the anterior segment. J Proteome. 2020;225:103881.

17. Schulze U, Hampa L, Sel S, Contreras-Ruiz L, Schicht M, Dieckow J, et al. Trefoil factor family peptide 3 (TFF3) is upregulated with experimental conditions similar to dry eye disease and supports corneal wound healing effects in vitro. Invest Ophthalmol Vis Sci. 2014;55(3):3037–42.

18. Stephenson DN, McNama NA. Altered mucin and glycoprotein expression in dry eye disease. Optom Proc Vis Sci. 2015;92(9):931–8.

19. Chiarantana P, Nolani EM. Defensins, lectins, mucins, and secretory immunoglobulins a: a microbe-binding molecules that contribute to mucosal immunity in the human gut. Crit Rev Biochem Mol Biol. 2017;52(1):145–56.

20. Paulsen FP, Berry MS. Mucins and TFF peptides of the tear film and lacrimal apparatus. Prog Histochem Cytochem. 2006;41(1):1–53.

21. Schulze U, Hampa L, Sel S, Contreras-Ruiz L, Schicht M, Dieckow J, et al. Trefoil factor family peptide 3 (TFF3) is upregulated with experimental conditions similar to dry eye disease and supports corneal wound healing effects in vitro. Invest Ophthalmol Vis Sci. 2014;55(3):3037–42.

22. Stephens DN, McNama NA. Altered mucin and glycoprotein expression in dry eye disease. Optom Proc Vis Sci. 2015;92(9):931–8.

23. Chiarantana P, Nolani EM. Defensins, lectins, mucins, and secretory immunoglobulins a: a microbe-binding molecules that contribute to mucosal immunity in the human gut. Crit Rev Biochem Mol Biol. 2017;52(1):145–56.

24. Kuo M-T, Fang P-C, Chao T-L, Chen A, Lai Y-H, Huang Y-T, et al. Tear proteomic approach to monitoring Sjögren syndrome or dry eye disease. Int J Mol Sci. 2019;20(8):1932.

25. Zhou L, Beuerman RW, Chan CM, Zhao SZ, Li XR, Yang H, et al. Identification of tear fluid biomarkers in dry eye syndrome using iTRAQ quantitative proteomics. J Proteome Res. 2009;8(11):4889–905.

26. Shiraf H, Daei-Niksen S, Hjortdal J, Karamichos D. Distinctive features of the tear proteome using iTRAQ and TMT-based isobaric labeling. Mass Spectrom Rev. 2018;37(5):583–606.

27. Pruptepe M, Berry MS. Mucins and TFF peptides of the tear film and lacrimal apparatus. Prog Histochem Cytochem. 2006;41(1):1–53.

28. Paulsen FP, Berry MS. Mucins and TFF peptides of the tear film and lacrimal apparatus. Prog Histochem Cytochem. 2006;41(1):1–53.

29. Babin MC, Ricketts KM, Gazaway MY, Lee RB, Sweeney RE, Brozetti JJ. A combination drug treatment against ocular sulfur mustard injury. J Toxicol. 2005;23(1):65–75.

30. Javadi K, Panahi Y, Ebrahimi A, Mafi M, Nejar F, Sahelbark A. Topical cyclosporine a for treatment of dry eye due to chronic mustard gas injury. J OphthalmicVis Sci. 2014;9(4):171.

31. Umadat V, Ihedioha O, Shi R, Uzonna J, Myal Y. The prolactin-inducible factor/TFF3 promotes re-epithelialization of corneal wounds. J Biol Chem. 2008;283(19):13418–27.

32. Ananthi S, Chitra T, Bini R, Prajna NV, Lalitha P, Dharmalingam K. Comparative proteomic analysis of the tear fluid proteome using iTRAQ and TMT-based isobaric labeling. Mass Spectrom Rev. 2018;37(5):157–60.

33. Shadforth IP, Dunkley TP, Lilleby KS, Bessant C. I-Tracker: for quantitative proteomics using iTRAQ™. BMC Genomics. 2005;6(1):145.

34. Moulder R, Bhosal SD, Goodlett DR, Lahesmaa R. Analysis of the plasma proteome using iTRAQ and TMT-based isobaric labeling. Mass Spectrom Rev. 2018;37(5):583–606.

35. Ibarra PS, D'Aquagio M, Fassina I, D'Aquagio M, Fassina I, D'Aquagio M, Fassina I, D'Aquagio M, Fassina I. The induction of anterior chamber-associated immune deviation. Immune Response and the Eye. 92. Karger Publishers, 2007. p. 27–35.

36. Mondino BJ, Chou HJ, Sun H-J, Bora PS, Bora NS. Chronic low level complement activation within the eye is controlled by intracellular complement regulatory proteins. Invest Ophthalmol Vis Sci. 2000;41(11):3492–502.

37. Niederkorn JY. The induction of anterior chamber-associated immune deviation. Immune Response and the Eye. 92. Karger Publishers, 2007. p. 27–35.

38. Mondino BJ, Chou HJ, Sun H-J, Bora PS, Bora NS. Chronic low level complement activation within the eye is controlled by intracellular complement regulatory proteins. Invest Ophthalmol Vis Sci. 2000;41(11):3492–502.

39. Niederkorn JY. The induction of anterior chamber-associated immune deviation. Immune Response and the Eye. 92. Karger Publishers, 2007. p. 27–35.
39. Tang A, Marquart ME, Fratkin JD, McCormick CC, Caballero AR, Gatlin HP, et al. Properties of PASP: a Pseudomonas protease capable of mediating corneal erosions. Invest Ophthalmol Vis Sci. 2009;50(8):3794–801.
40. Cocuzzi E, Guidubaldi J, Bardenstein DS, Chen R, Jacobs MR, Medof ME. Release of complement regulatory proteins from ocular surface cells in infections. Curr Eye Res. 2000;21(5):856–66.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.